Andrew Huberman: Peptides, Sleep Tech, and the End of Obesity

Daisy Wolf speaks with Dr. Andrew Huberman, professor of neurobiology and ophthalmology at Stanford University and host of the Huberman Lab podcast. They discuss how the pandemic sparked a consumer health revolution, the emerging peptide and GLP landscape, what the science actually says about focus drugs, and the neurotechnologies Huberman believes will let us write to our own biology within the next five years. Timestamps: 0:00—Introduction 1:15—The Health Awakening, Explained 7:02—MAHA's Role in the Health Movement 13:05—GLP-1: Nearly One in Seven Americans 18:37—The Non-GLP Peptide Craze 25:16—Rogue Experiments and Low-Dose GLP 31:40—Real-Time Cortisol Sensing 44:39—The Pet Octopus and AI Communication Resources: Follow Andrew Huberman on X: https://twitter.com/hubermanlab Follow Daisy on X https://twitter.com/daisydwolf Stay Updated: If you enjoyed this episode, be sure to like, subscribe, and share with your friends! Find a16z on X: https://twitter.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Listen to the a16z Show on Spotify: https://open.spotify.com/show/5bC65RDvs3oxnLyqqvkUYX Listen to the a16z Show on Apple Podcasts: https://podcasts.apple.com/us/podcast/a16z-podcast/id842818711 Follow our host: https://x.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see http://a16z.com/disclosures.